Weight loss clinic marketing: FTC, FDA and ad platform rules

Medical weight loss is one of the most heavily regulated areas a practice can advertise in. Claims about results are scrutinized by the FTC, prescription drug promotion is restricted by both Meta and Google, and the FDA has published specific concerns about compounded and unapproved versions of GLP-1 drugs. A clinic that markets the way general wellness brands do can run into all three at once.

This guide covers the rules that shape the marketing, not the medicine. It does not discuss dosing, eligibility or treatment choices, which are clinical decisions for licensed prescribers. Whether a program can be described as payable from an HSA or FSA is covered in HSA and FSA eligible claims in practice ads. Pinterest limits weight loss ads further, as our guide to Pinterest for medical practices explains. Body contouring is not weight loss treatment; see body contouring marketing.

The FDA position on compounded GLP-1 drugs

The FDA keeps a dated page on its policies for compounders as GLP-1 supply stabilized. On December 19, 2024, it determined that the tirzepatide injection shortage was resolved. On February 21, 2025, it determined that the semaglutide injection shortage was resolved. The enforcement grace periods it announced for compounders have since ended, and in its April 1, 2026 update the FDA states that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on the FDA drug shortage list.

The same page states that compounded drugs are not approved by FDA, and that they must meet conditions to qualify for the exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Whether and how a compounded product can be prescribed is a question for your prescribers, your pharmacy and your attorney. What it means for marketing is more direct:

• Do not call a compounded product “FDA approved”. The FDA says compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before they are marketed.
• Do not say a compounded product is “the same as” or a “generic” version of an approved brand. The FDA lists claims that a compounded drug is the same as an FDA-approved drug among its red flags for consumers.
• Do not use a brand-name product’s images, name or results to sell a different product.
• Do not promote low prices as the main message. Deep discounts that seem too good to be true are also on the FDA’s list of warning signs.

The FDA’s page on unapproved GLP-1 drugs used for weight loss also warns about products sold falsely labeled “for research purposes” or “not for human consumption”. A clinic should not be associated with any such product in its marketing.

FTC rules on weight loss claims

The FTC’s Health Products Compliance Guidance applies to claims about any health-related product or service. It says claims about health benefits must be backed by competent and reliable scientific evidence, and that, as a general matter, this means randomized, controlled human clinical testing. It also says an ad can make implied claims through images, such as lab coats and medical journals, that convey a product has been clinically proven.

For a clinic, the claim is usually about the program as a whole: the visits, the prescriber, the support. Be careful with specific numbers, timeframes and words like “guaranteed”, “effortless” or “permanent”. The FTC’s Gut Check guide lists seven weight loss claims experts say simply cannot be true for supplements, over-the-counter drugs and products worn or rubbed on, including weight loss without dieting or exercise, permanent weight loss after stopping the product, and substantial weight loss for all users. Those claims are a useful list of phrases to keep out of any weight loss ad.

Surgical programs face the same claim rules with added questions about candidacy, surgical risks, disease claims such as diabetes remission, accreditation wording and Medicare coverage. Those are covered in our guide to bariatric surgery program marketing. Primary care practices that offer the Medicare benefit for intensive behavioral counseling should read our guide to Medicare obesity counseling outreach.

Testimonials and typical results

Patient stories are where weight loss marketing most often goes wrong. Under 16 CFR 255.2(b), an ad with a consumer endorsement about a key attribute of the product will likely be read as saying the endorser’s experience is what people will generally achieve. If the advertiser does not have substantiation for that, the ad should clearly and conspicuously disclose the generally expected performance.

The FTC’s Health Products Compliance Guidance adds that advertisers should not make claims through testimonials that would be deceptive or could not be substantiated if made directly, and that an honest opinion from the endorser is not enough. The Gut Check guide notes that the endorsement rules apply to all weight loss products, programs and services.

Patient stories also raise HIPAA authorization questions when a practice uses them. Our guide to patient testimonials and before-and-after photos covers the FTC and HIPAA rules in detail. Many clinics decide that their marketing will describe the program and the team instead.

Meta ad policies for weight loss

Meta’s Health and Wellness ad policy says ads for weight loss or weight gain products and services must be targeted to people at least 18 years old. The same policy prohibits ads that:

• Contain statements of inferiority about physical appearance, such as negative terms or questions that attack a person’s appearance or body parts.
• Show a close-up of a specific body area by pinching fat.
• Use clickbait, such as sensational language or promises of specific outcomes within a set timeframe without disclaimers or qualifiers.

For weight loss products that require a prescription, the policy points to Meta’s Drugs and Pharmaceuticals policy. That policy says online pharmacies and telehealth providers must be actively certified with LegitScript and request authorization from Meta, and that prescription drug ads may only target people 18 or older in eligible countries, which it lists as the United States, Canada and New Zealand, with a disclaimer to consult a licensed health professional or obtain a valid prescription.

Google Ads policies for weight loss and prescription drugs

Google’s Healthcare and medicines policy restricts several things a weight loss clinic may want to do:

1. Prescription drug terms. In the United States, Google says you do not need certification to use prescription drug terms in ads and landing pages, but you must be certified to keyword-target those terms.
2. Prescription drug services. Online prescribing, dispensing and sale of prescription drugs, including by telemedicine providers, requires Google certification. For the United States, the policy says telemedicine providers must be accredited by LegitScript’s Healthcare Merchant Certification Program, and advertisers must also be certified with Google.
3. Prescriptions. The policy says offering prescription drugs without a prescription is not allowed.
4. Unapproved substances. The policy prohibits products containing human chorionic gonadotropin (hCG) in relation to weight loss or weight control, and products that imply they are as effective as prescription drugs.

A clinic whose ads promote an in-person program, a consultation and a medical team is in a different position from one selling prescriptions online. Our guide to healthcare ad policy basics covers the general rules, and telehealth marketing for practices covers virtual visits.

What a weight loss clinic can say

Within these rules there is still a lot to communicate, and it is often what prospective patients want to know first:

• Who the prescribers and team are, with their real credentials.
• What the first visit involves, and that treatment decisions are made by a licensed clinician after an evaluation.
• Which services you offer, such as nutrition counseling or medically supervised programs, described plainly.
• Prices or how pricing works, if you choose to publish it, stated accurately.
• Hours, locations, insurance or self-pay policies and how to book.

Leave out before-and-after images, pounds-lost numbers, timeframes and anything that describes a compounded drug as approved or equivalent to a brand.

How we help

We build weight loss clinic websites and campaigns around the program and the clinicians, with no results claims, and we check the current Meta and Google policies for each service before an ad runs. We do not give legal or medical advice. See our Google Ads for practices and med spa marketing services, or the full list in our healthcare marketing rules guide.

Frequently asked questions

Sources

• FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updates dated October 2, 2024 to April 1, 2026)
• FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss
• FTC: Health Products Compliance Guidance (December 2022)
• FTC: Gut Check, a reference guide for media on spotting false weight loss claims
• 16 CFR 255.2: Consumer endorsements
• Meta: Health and Wellness ad policy
• Meta: Drugs and Pharmaceuticals ad policy
• Google Ads: Healthcare and medicines policy
• Google Ads: Prescription drug services policy

More in Cash-pay, aesthetic and wellness care